About: Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 March 1992

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в березні 1992 (uk) article scientifique publié en 1992 (fr) artículu científicu espublizáu en marzu de 1992 (ast) im März 1992 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 01 March 1992 (en)
publication date	wds:Q68134858-86B07887-B2EF-41C5-8225-4732D9A92839
publication date	1992-03-01 00:00:00Z (xsd:dateTime)
cites work	wds:Q68134858-0A969F9E-F9FD-4AAA-826F-3C0F0698F4A1 wds:Q68134858-1EEBDC94-A53A-449A-B1D3-F81E321D6DF4 wds:Q68134858-27892069-B3A1-4D41-9F9A-3E8EDA284A42 wds:Q68134858-2B6970AB-90C4-49CA-B8F9-83389ECFF3EE wds:Q68134858-31C2E370-B71A-4D80-8C9F-4CABBF4385DD wds:Q68134858-46C7307C-04AB-4161-829E-894538B4FBDF wds:Q68134858-49794BB5-B686-468E-ACC4-2FD1A24E61B4 wds:Q68134858-5F37A1DE-C4FA-4F02-B381-5709ACAF244C wds:Q68134858-66FC3D5F-AC15-441F-8854-DC22EFDFBCFC wds:Q68134858-671A9B9F-4FDD-465D-B43D-0FF7B3EF4779 wds:Q68134858-671D7DB1-E52A-4633-9EBA-A95A5752CE6B wds:Q68134858-68AA1256-8B47-4AAB-B49B-DABDDFF2A902 wds:Q68134858-855EFEB8-1390-497A-9B64-819BD47B7B06 wds:Q68134858-8EDD49BD-8882-4FC0-9B32-C42019CE3EB1 wds:Q68134858-967528AE-C19C-4914-A246-D9154366E0B9 wds:Q68134858-99DDF936-4A09-4823-8513-B584824EAD5A wds:Q68134858-A8B9F660-43E2-4305-978D-1073B9487B1B wds:Q68134858-B0D2DF41-EA87-4FB8-8C17-E4ECDA800C8B wds:Q68134858-B4532A71-27D0-45B5-914C-F5116806028E wds:Q68134858-B72C001A-6F19-4FCA-8547-4E91DE79BF29 wds:Q68134858-B87410FE-A4A3-416C-AFF5-1F1C5CED76FE wds:Q68134858-C9265DA5-3887-4B4C-9C66-BE9328FDF39B wds:Q68134858-D06CF72E-A8F8-41BB-BCEC-182034E9D38B wds:Q68134858-D56A33A6-92F5-47E2-9544-CC8099188B14 wds:Q68134858-EC7C360A-8141-493B-AAC8-89D8E8A4A07B wds:Q68134858-F8E3A7D7-B741-42D6-82E5-60ECDE34F2C3 wds:Q68134858-FA2DFA88-AEC2-4DB3-8D51-7CC26450B9D0
cites work	VP 16-213 and cytosine-arabinoside combination chemotherapy for refractory acute lymphoblastic leukemia in adults Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial Results of MIME salvage regimen for recurrent or refractory lymphoma Histological transformation of non-hodgkin's lymphoma.A prospective study Follicular lymphoma: prognostic factors for response and survival The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphomas High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213 Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD Advances in the Treatment of Acute Myelogenous Leukemia Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study High-dose cytosine arabinoside. Active agent in treatment of non-Hodgkin's lymphoma High-dose cytosine arabinoside in non-Hodgkin's lymphoma How can we cure leukaemia? High dose cytosine arabinoside (HDARAC) in refractory acute leukemia Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma Etoposide and cytosine arabinoside combination chemotherapy for refractory acute lymphocytic leukemia in childhood Drugs five years later: cytarabine Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia.
author name string	wds:Q68134858-09A739F9-ACA6-48AF-9936-CF2375FC9BE8 wds:Q68134858-0A49B8AE-D806-4BFE-8CE8-29BEE56D538E wds:Q68134858-4643C05A-8A03-4EB8-80EE-C96EE4F545B5 wds:Q68134858-56DAF721-EC07-4011-BA47-9D32BF844AA0 wds:Q68134858-7E492490-799A-4621-8707-7B4C09F2E354 wds:Q68134858-7F2A41B7-1C4A-467B-A1C3-A0A14605FFEA wds:Q68134858-8A717683-35A5-489B-AD9D-A257D3131194 wds:Q68134858-C9DEFB7A-21FD-4A71-9629-56ADB52EDF74 wds:Q68134858-D899705D-28CE-4B20-B7FF-C69720DFFFD0 wds:Q68134858-E38C4E15-6764-473E-B312-E4C7F0D15C93
author name string	Leahy M Gupta RK Amess JA Matthews J Davis CL Lister TA Rohatiner AZ Norton AJ MacCallum PK Whelan JS
rdfs:label	Etoposide in combination with intermediate dose cytosine arabinoside (nl) Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy (en)
skos:prefLabel	Etoposide in combination with intermediate dose cytosine arabinoside (nl) Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy (en)
name	Etoposide in combination with intermediate dose cytosine arabinoside (nl) Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy (en)
title	wds:Q68134858-154EF078-24A6-411B-A1C9-7B4DD06A933A
title	Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy (en)
page(s)	wds:Q68134858-FD0EBDAD-15AE-441D-A9CA-CB5DFFB3F0E5
page(s)	87-94
instance of	wds:Q68134858-0B2ACF76-CCEB-47C3-A8BD-8F75A1E7814A
instance of	scholarly article
main subject	wds:Q68134858-D27609A9-32FA-4A56-A188-3C260B6DAE3F wds:Q68134858-DD2DA67D-CF42-4C4B-AD60-246521FE405D
main subject	wd:Q180983 wd:Q418817
PubMed ID	wds:Q68134858-2540048A-86FF-4226-8521-8BAEEC0D5B58

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software